{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:17:39Z","timestamp":1761808659073,"version":"build-2065373602"},"reference-count":155,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Remarkable advancements have been made in the treatment outcomes of multiple myeloma (MM) patients; however, for frail elderly patients, these treatment outcomes are still insufficient. Elderly MM patients are increasing, as are their treatment regimens. There is a heightened demand to assess these patients in order to provide optimized treatments. While continuous treatment is more common for MM patients when compared to fixed-duration treatment, due to the risk of treatment interruption causing reduced survival rates, effectiveness and safety are essential. Treatment goals vary for each patient, but must preserve their quality of life (QOL). When planning treatments for these patients, frailty evaluation is increasingly emphasized as a stratification factor which helps develop accurate screening tools. Daratumumab (DARA) therapy, used globally, is not only effective in frail elderly MM patients, but also has QOL benefits. Proficiency in utilizing DARA regimens is potentially advantageous for patients not included in clinical trials, and innovative usage can further broaden its scope. The development of tools to accurately assess frailty and the establishment of optimal treatments for frail elderly MM patients are imperative. This review is an overview, challenging the frailty assessments for MM patients, re-examining the evidence for DARA regimens in frail elderly MM patients, and discussing potential areas for improvement.<\/jats:p>","DOI":"10.3390\/life14030389","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T12:02:39Z","timestamp":1710504159000},"page":"389","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Daratumumab Treatment for \u201cTruly Frail\u201d Elderly Myeloma Patients"],"prefix":"10.3390","volume":"14","author":[{"given":"Yuichi","family":"Horigome","sequence":"first","affiliation":[{"name":"Department of Hematology, Kitasato University Graduate School of Medical Sciences, Sagamihara 252-0373, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0300-378X","authenticated-orcid":false,"given":"Kazuhito","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Minato City 105-8461, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kitasato University Graduate School of Medical Sciences, Sagamihara 252-0373, Kanagawa, Japan"},{"name":"Department of Hematology, Kitasato University School of Medicine, Sagamihara 252-0374, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s12094-020-02541-1","article-title":"Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study","volume":"23","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1200\/JCO.2014.55.1028","article-title":"Multiple myeloma in the older adult: Better prospects, more challenges","volume":"32","author":"Wildes","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11912-019-0804-4","article-title":"Management of Newly Diagnosed Elderly Multiple Myeloma Patients","volume":"21","author":"Braunstein","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.3324\/haematol.2017.173617","article-title":"Treat or palliate: Outcomes of very elderly myeloma patients","volume":"103","author":"Panitsas","year":"2018","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): Overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of POLLUX","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: Extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials","volume":"98","author":"Bringhen","year":"2013","journal-title":"Haematologica"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: Evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1159\/000492272","article-title":"Decision Making Criteria in Oncology","volume":"98","author":"Glatzer","year":"2020","journal-title":"Oncology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/CCO.0000000000000792","article-title":"Geriatric assessments and frailty scores in multiple myeloma patients: A needed tool for individualized treatment?","volume":"33","author":"Gengenbach","year":"2021","journal-title":"Curr. Opin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0950-3536(05)80259-8","article-title":"The role of chemotherapy in the treatment of multiple myeloma","volume":"8","author":"Bergsagel","year":"1995","journal-title":"Baillieres Clin. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3026(18)30220-5","article-title":"A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): A development and validation study","volume":"6","author":"Cook","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/ajh.24532","article-title":"N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma","volume":"91","author":"Milani","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","article-title":"Studies of illness in the aged. The index of Adl: A standardized measure of biological and psychosocial function","volume":"185","author":"Katz","year":"1963","journal-title":"JAMA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: Self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/S1470-2045(18)30348-6","article-title":"Functional versus chronological age: Geriatric assessments to guide decision making in older patients with cancer","volume":"19","author":"Li","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.2006.09.7865","article-title":"Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation","volume":"25","author":"Sorror","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0021-9681(74)90017-4","article-title":"The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus","volume":"27","author":"Kaplan","year":"1974","journal-title":"J. Chronic Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7326\/0003-4819-120-2-199401150-00002","article-title":"The effect of comorbidity on 3-year survival of women with primary breast cancer","volume":"120","author":"Satariano","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/bcj.2011.34","article-title":"Comorbidity as a prognostic variable in multiple myeloma: Comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score","volume":"1","author":"Kleber","year":"2011","journal-title":"Blood Cancer J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/cam4.1128","article-title":"The impact of comorbidity on mortality in multiple myeloma: A Danish nationwide population-based study","volume":"6","author":"Gregersen","year":"2017","journal-title":"Cancer Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41408-023-00843-5","article-title":"Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study","volume":"13","author":"Mian","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): A multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e056147","DOI":"10.1136\/bmjopen-2021-056147","article-title":"Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): A study protocol for a randomised phase III trial","volume":"12","author":"Coulson","year":"2022","journal-title":"BMJ Open"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/S2152-2650(21)02289-8","article-title":"P-162: Compass: A prospective study comparing clinical evaluation with different geriatric screening methods in newly diagnosed elderly multiple myeloma patients","volume":"21","author":"Delforge","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1046\/j.1532-5415.2001.49281.x","article-title":"The Vulnerable Elders Survey: A tool for identifying vulnerable older people in the community","volume":"49","author":"Saliba","year":"2001","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jgo.2021.03.015","article-title":"Integrating geriatric screening in the clinical setting: Recommendations for older adult oncology patients","volume":"12","author":"McClennon","year":"2021","journal-title":"J. Geriatr. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1200\/JCO.2017.72.8170","article-title":"Time to Stop Saying Geriatric Assessment Is Too Time Consuming","volume":"35","author":"Hamaker","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: Back to the future","volume":"131","author":"Richardson","year":"2018","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1158\/1078-0432.CCR-17-2027","article-title":"Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab","volume":"23","author":"Krejcik","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.3324\/haematol.2019.219683","article-title":"Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed\/refractory multiple myeloma patients","volume":"105","author":"Kitadate","year":"2020","journal-title":"Haematologica"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2020)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1093\/oncolo\/oyad053","article-title":"Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma","volume":"28","author":"Fonseca","year":"2023","journal-title":"Oncologist"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/ajh.25963","article-title":"Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma","volume":"95","author":"Durie","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3389\/fimmu.2018.01676","article-title":"CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance","volume":"9","author":"Seckinger","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.clml.2019.09.623","article-title":"Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR","volume":"20","author":"Mateos","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): An open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: Frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.clml.2021.06.005","article-title":"Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE","volume":"21","author":"Mateos","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.20.03143","article-title":"Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study","volume":"39","author":"Stege","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","article-title":"Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network","volume":"32","author":"Ludwig","year":"2018","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2012-05-427815","article-title":"Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial","volume":"120","author":"Mateos","year":"2012","journal-title":"Blood"},{"key":"ref_59","first-page":"966","article-title":"Recent advances in the management of older adults with newly diagnosed multiple myeloma in Japan","volume":"52","author":"Suzuki","year":"2022","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/bjh.15879","article-title":"Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed\/refractory multiple myeloma (GEN503): Final results of an open-label, phase 1\/2 study","volume":"186","author":"Plesner","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3324\/haematol.2019.217448","article-title":"Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: Subgroup analysis of the phase 3 CASTOR and POLLUX studies","volume":"105","author":"Mateos","year":"2020","journal-title":"Haematologica"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.21.02734","article-title":"Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial","volume":"41","author":"Sonneveld","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1182\/bloodadvances.2020001965","article-title":"Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and\/or refractory multiple myeloma","volume":"4","author":"Facon","year":"2020","journal-title":"Blood Adv."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): Interim analysis results of a randomised, phase 3 study","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study","volume":"7","author":"Usmani","year":"2023","journal-title":"Blood Adv."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/01.HS9.0000846500.86746.52","article-title":"P907: Carfilzomib, dexamethasone, and daratumumab (kdd) vs carfilzomib and dexamethasone (kd) in relapsed\/refractory multiple myeloma (rrmm): Frailty subgroup analysis of the candor study","volume":"6","author":"Quach","year":"2022","journal-title":"HemaSphere"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/bjh.16980","article-title":"Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): An open-label Phase II study","volume":"192","author":"Chari","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood.2019000722","article-title":"Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Chari","year":"2019","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41408-023-00805-x","article-title":"Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: Final analysis of PLEIADES and EQUULEUS","volume":"13","author":"Moreau","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1182\/blood-2022-163483","article-title":"Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study","volume":"140","author":"Dimopoulos","year":"2022","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","article-title":"Geriatric assessment in multiple myeloma patients: Validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores","volume":"101","author":"Engelhardt","year":"2016","journal-title":"Haematologica"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.29119","article-title":"Health-related quality of life in older adult survivors of selected cancers: Data from the SEER-MHOS linkage","volume":"121","author":"Kent","year":"2015","journal-title":"Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.0902-4441.2003.00195.x","article-title":"Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences","volume":"72","author":"Gulbrandsen","year":"2004","journal-title":"Eur. J. Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","article-title":"Health related quality of life in a nationally representative sample of haematological patients","volume":"83","author":"Johnsen","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Ramsenthaler, C., Osborne, T.R., Gao, W., Siegert, R.J., Edmonds, P.M., Schey, S.A., and Higginson, I.J. (2016). The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: A multi-centre study. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2410-2"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/leu.2013.185","article-title":"Review of health-related quality of life data in multiple myeloma patients treated with novel agents","volume":"27","author":"Sonneveld","year":"2013","journal-title":"Leukemia"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/17474086.2019.1613886","article-title":"Quality of life in multiple myeloma: Considerations and recommendations","volume":"12","author":"Seitzler","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.6004\/jnccn.2020.7561","article-title":"Symptom Burden, Perceived Control, and Quality of Life Among Patients Living With Multiple Myeloma","volume":"18","author":"Zaleta","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1002\/cncr.33658","article-title":"Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort","volume":"127","author":"Scheubeck","year":"2021","journal-title":"Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2217\/fon-2019-0368","article-title":"Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics","volume":"15","author":"Anderson","year":"2019","journal-title":"Future Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): A multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/jcph.1771","article-title":"Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients","volume":"61","author":"Luo","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.3324\/haematol.2021.279459","article-title":"Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma","volume":"107","author":"Usmani","year":"2022","journal-title":"Haematologica"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1063144","DOI":"10.3389\/fonc.2023.1063144","article-title":"Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers","volume":"13","author":"Cook","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2012.01788.x","article-title":"Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: Results from the VISTA trial","volume":"89","author":"Delforge","year":"2012","journal-title":"Eur. J. Haematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1182\/blood.V118.21.1864.1864","article-title":"Patient-Reported Quality of Life (QoL) in Elderly, Newly Diagnosed Multiple Myeloma (MM) Patients Receiving Bortezomib-Based Combinations: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study","volume":"118","author":"Niesvizky","year":"2011","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3324\/haematol.2013.099341","article-title":"Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy","volume":"99","author":"Mateos","year":"2014","journal-title":"Haematologica"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Knop, S., Mateos, M.V., Dimopoulos, M.A., Suzuki, K., Jakubowiak, A., Doyen, C., Lucio, P., Nagy, Z., Usenko, G., and Pour, L. (2021). Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: Results from the randomized phase III ALCYONE trial. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08325-2"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3324\/haematol.2014.120121","article-title":"Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: Lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide","volume":"100","author":"Delforge","year":"2015","journal-title":"Haematologica"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"8016","DOI":"10.1200\/JCO.2019.37.15_suppl.8016","article-title":"Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA","volume":"37","author":"Perrot","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.20.01370","article-title":"Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial","volume":"39","author":"Perrot","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/bjh.17321","article-title":"Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: Results from the phase III CASTOR trial","volume":"193","author":"Hungria","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/bjh.17435","article-title":"Health-related quality of life in patients with relapsed or refractory multiple myeloma: Treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial","volume":"194","author":"Plesner","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1080\/10428194.2021.1941927","article-title":"Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma","volume":"62","author":"Siegel","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ajh.26480","article-title":"Health-related quality of life in patients with relapsed\/refractory multiple myeloma treated with pomalidomide and dexamethasone \u00b1 subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial","volume":"97","author":"Terpos","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1182\/bloodadvances.2020002218","article-title":"Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities","volume":"4","author":"Abdallah","year":"2020","journal-title":"Blood Adv."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project","volume":"40","author":"Cairns","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41375-019-0595-5","article-title":"The relative importance of factors predicting outcome for myeloma patients at different ages: Results from 3894 patients in the Myeloma XI trial","volume":"34","author":"Pawlyn","year":"2020","journal-title":"Leukemia"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0037-1963(01)90020-4","article-title":"Myeloma bone disease","volume":"38","author":"Callander","year":"2001","journal-title":"Semin. Hematol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/leu.2010.62","article-title":"Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","article-title":"Myeloma bone disease: From biology findings to treatment approaches","volume":"133","author":"Terpos","year":"2019","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.2019000758","article-title":"Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/cncr.33344","article-title":"Gait speed, survival, and recommended treatment intensity in older adults with blood cancer requiring treatment","volume":"127","author":"Hantel","year":"2021","journal-title":"Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e000049","DOI":"10.1136\/rmdopen-2015-000049","article-title":"The osteocyte: Key player in regulating bone turnover","volume":"1","author":"Goldring","year":"2015","journal-title":"RMD Open"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00774-023-01403-4","article-title":"Myeloma bone disease: Pathogenesis and management in the era of new anti-myeloma agents","volume":"41","author":"Teramachi","year":"2023","journal-title":"J. Bone Miner Metab."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Terpos, E., Ntanasis-Stathopoulos, I., Kastritis, E., Hatjiharissi, E., Katodritou, E., Eleutherakis-Papaiakovou, E., Verrou, E., Gavriatopoulou, M., Leonidakis, A., and Manousou, K. (2022). Daratumumab Improves Bone Turnover in Relapsed\/Refractory Multiple Myeloma; Phase 2 Study \u201cREBUILD\u201d. Cancers, 14.","DOI":"10.3390\/cancers14112768"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1038\/bcj.2015.20","article-title":"Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma","volume":"5","author":"Gonsalves","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"E226","DOI":"10.1002\/ajh.27001","article-title":"Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed\/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study","volume":"98","author":"Kastritis","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1111\/bjh.17412","article-title":"Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure","volume":"193","author":"Kuzume","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1111\/bjh.16286","article-title":"Single-agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: Results of a Spanish retrospective, multicentre study","volume":"190","author":"Cejalvo","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2215\/CJN.11161111","article-title":"Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases","volume":"7","author":"Leung","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1681\/ASN.2010080857","article-title":"Early reduction of serum-free light chains associates with renal recovery in myeloma kidney","volume":"22","author":"Hutchison","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ajh.24335","article-title":"Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis","volume":"91","author":"Dimopoulos","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cger.2009.07.007","article-title":"The burden of cardiovascular disease in the elderly: Morbidity, mortality, and costs","volume":"25","author":"Yazdanyar","year":"2009","journal-title":"Clin. Geriatr. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-019-0183-y","article-title":"Management of cardiovascular risk in patients with multiple myeloma","volume":"9","author":"Plummer","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Terpos, E., Stamatelopoulos, K., Makris, N., Georgiopoulos, G., Ntanasis-Stathopoulos, I., Gavriatopoulou, M., Laina, A., Eleutherakis-Papaiakovou, E., Fotiou, D., and Kanellias, N. (2021). Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed\/Refractory Multiple Myeloma: A Prospective Study. Cancers, 13.","DOI":"10.3390\/cancers13205057"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"C297","DOI":"10.1152\/ajpcell.00139.2017","article-title":"Characterization of CD38 in the major cell types of the heart: Endothelial cells highly express CD38 with activation by hypoxia-reoxygenation triggering NAD(P)H depletion","volume":"314","author":"Boslett","year":"2018","journal-title":"Am. J. Physiol.-Cell Physiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jcb.29334","article-title":"Effect of miR-499a-5p on damage of cardiomyocyte induced by hypoxia-reoxygenation via downregulating CD38 protein","volume":"121","author":"Zhao","year":"2020","journal-title":"J. Cell Biochem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: A population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/s41375-018-0142-9","article-title":"Patient-centered practice in elderly myeloma patients: An overview and consensus from the European Myeloma Network (EMN)","volume":"32","author":"Larocca","year":"2018","journal-title":"Leukemia"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): A multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5045\/br.2021.2021176","article-title":"Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen","volume":"57","author":"Kim","year":"2022","journal-title":"Blood Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma","volume":"39","author":"Gleason","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjh.17608","article-title":"Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma","volume":"195","author":"Avivi","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3026(21)00110-1","article-title":"Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma","volume":"8","author":"Bird","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-021-01090-6","article-title":"Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: Preliminary data from a single institution","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s41375-023-01920-1","article-title":"Management of patients with multiple myeloma and COVID-19 in the post pandemic era: A consensus paper from the European Myeloma Network (EMN)","volume":"37","author":"Terpos","year":"2023","journal-title":"Leukemia"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Johnson, B.H., Palmer, L., Gatwood, J., Lenhart, G., Kawai, K., and Acosta, C.J. (2015). Annual incidence rates of herpes zoster among an immunocompetent population in the United States. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-1262-8"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/j.1742-1241.2009.02089.x","article-title":"Postherpetic neuralgia in the elderly","volume":"63","author":"Johnson","year":"2009","journal-title":"Int. J. Clin. Pract."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00277-019-03621-1","article-title":"The risk of infections in multiple myeloma before and after the advent of novel agents: A 12-year survey","volume":"98","author":"Brioli","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: An infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)","volume":"24","author":"Drgona","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0140-6736(18)30631-7","article-title":"Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: An international, multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Winston","year":"2018","journal-title":"Lancet"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: A consensus of the European Myeloma Network","volume":"35","author":"Ludwig","year":"2021","journal-title":"Leukemia"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/j.clml.2020.12.026","article-title":"Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma","volume":"21","author":"Lancman","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood.2020009507","article-title":"Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma","volume":"137","author":"Larocca","year":"2021","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1158\/1078-0432.CCR-22-3181","article-title":"Corticosteroids and Cancer Immunotherapy","volume":"29","author":"Goodman","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/10428194.2022.2148221","article-title":"Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: Part 3 of the open-label, multicenter, phase 1b PAVO study","volume":"64","author":"Nahi","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood.2019000667","article-title":"Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"key":"ref_150","first-page":"1725","article-title":"Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)","volume":"106","author":"Usmani","year":"2021","journal-title":"Haematologica"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2022-159933","article-title":"A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial","volume":"140","author":"Manier","year":"2022","journal-title":"Blood"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2021-148152","article-title":"Ixazomib and Daratumumab without Dexamethasone (I-Dara) in Elderly Frail RRMM Patients. a Multicenter Phase 2 Study (IFM 2018-02) of the Intergroupe Francophone Du My\u00e9lome (IFM)","volume":"138","author":"Macro","year":"2021","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"TPS8056","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8056","article-title":"Bortezomib, lenalidomide, and dexamethasone (VRd) \u00b1 daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS)","volume":"37","author":"Zweegman","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1007\/s00277-022-04917-5","article-title":"Anti-CD38 antibody therapy for patients with relapsed\/refractory multiple myeloma: Differential mechanisms of action and recent clinical trial outcomes","volume":"101","author":"Leleu","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41375-021-01431-x","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG-CONCEPT trial","volume":"36","author":"Leypoldt","year":"2022","journal-title":"Leukemia"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/3\/389\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:14:16Z","timestamp":1760105656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/3\/389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":155,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["life14030389"],"URL":"https:\/\/doi.org\/10.3390\/life14030389","relation":{},"ISSN":["2075-1729"],"issn-type":[{"type":"electronic","value":"2075-1729"}],"subject":[],"published":{"date-parts":[[2024,3,15]]}}}